RECRUITING STUDIES

Asthma

Dr. Curtis Veal is conducting a study for patients with asthma. The study evaluates the risk of serious asthma-related events during treatment with the study drug (a combination of two drugs, inhaled corticosteroid and a type of bronchodilator called a long-acting beta agonist) as compared to treatment with inhaled corticosteroid alone in the treatment of asthma.

Principal Investigator: Curtis Veal, MD
Sub-Investigators: Linda Anderson, MD; Charles Lee, MD; Samuel Nadler, MD; Embra Roper, MD
Study Coordinator: Gary Brown, CMA
Phone: (206) 860-4761
E-mail: research@polyclinic.com

 

Celiac Disease

Dr. Craig Pepin is conducting a study for patients with celiac disease maintained on a gluten-free diet who have experienced at least one moderate or severe symptom in the past month. The study evaluates the effectiveness and safety of an investigational agent (administered orally) in the management of celiac disease.

Principal Investigator: Craig Pepin, MD
Study Coordinator: Gary Brown, CMA
Phone: (206) 860-4761
E-mail: research@polyclinic.com

 

Diabetes (Type 2)

Dr. Ken Gross is conducting a study for type 2 diabetes patients. The study evaluates the effectiveness of an investigational agent (self-administered subcutaneously) on glycemic control in patients with type 2 diabetes.

Principle Investigator: Ken Gross, MD
Sub-Investigator: Michael Williams, MD
Study Coordinator: Kenita Davis, CMA
Phone: (206) 320-6766
E-mail: research@polyclinic.com

 

Diabetes (Type 2)

Dr. Ken Gross is conducting a study for type 2 diabetes patients. The study evaluates the safety and effectiveness of an investigational agent (administered orally) compared to sitagliptin in patients with type 2 diabetes who are taking metformin and a sulfonylurea.

Principle Investigator: Ken Gross, MD
Sub-Investigator: Michael Williams, MD
Study Coordinator: Kenita Davis, CMA
Phone: (206) 320-6766
E-mail: research@polyclinic.com

 

Multiple Sclerosis (Relapsing)

Dr. Braden Nago is conducting a study for patients with relapsing MS. The study evaluates the effectiveness and safety of an investigational agent (administered orally) in the treatment of relapsing MS.

Principle Investigator: Braden Nago, MD
Sub-Investigators: Alex Cooper, MD; Sameer Khan, MD; Anthony Krajcer, MD; Benduan Yang, MD
Study Coordinator: Michelle Harder, CMA
Phone: (206)860-5432
E-mail: research@polyclinic.com

 

Overactive Bladder 

Dr. Emily Bradley is conducting a study for patients with overactive bladder and urinary incontinence. The study evaluates the relative safety and effectiveness of Botox in achieving 100% reduction in urinary incontinence.

Principal Investigator: Emily Bradley, MD
Sub-Investigator: Van Ginger, MD, PhD
Study Coordinator: Kenita Davis, CMA 
Phone: (206) 320-6766
E-mail: research@polyclinic.com

 

Psoriatic Arthritis

Dr. Anthony Krajcer is conducting a study for patients with psoriatic arthritis. The study evaluates the effectiveness and safety of an investigational agent (administered subcutaneously) in treating psoriatic arthritis.

Principal Investigator: Anthony Krajcer, MD
Study Coordinator: Michelle Harder, CMA
Phone: (206) 860-5432
E-mail: research@polyclinic.com

 

Warfarin Use

Dr. Christopher Cannon is conducting a study to determine if using warfarin-related pharmacogenetic information in calculating warfarin doses will change the incidence of warfarin-related clinical events when compared to warfarin doses calculated without pharmacogenetic data.

Principal Investigator: Christopher Cannon, MD
Sub-Investigator: Melissa Hull, PharmD
Study Coordinator: Victoria Saetern, CMA 
Phone: (206) 320-6752 
E-mail: research@polyclinic.com